Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526666 · ClinicalTrials.gov registry record
Ascorbic Acid Levels in MDS, AML, and CMML Patients
A clinical trial of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Van Andel Research Institute.
- Completed
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT03526666 is a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that has completed, run by Van Andel Research Institute. The registered enrollment target is 50 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03526666, a study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, has completed, sponsored by Van Andel Research Institute.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is a non-interventional, specimen collection translational study to evaluate vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.
Conditions Studied
Interventions
- OTHER Peripheral blood collection
Study Locations (2)
Michigan
- Cancer and Hematology Centers of Western Michigan - Grand Rapids
- Metro Health - University of Michigan Health - Wyoming
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2018-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03526666
The ClinicalTrials.gov registry entry for NCT03526666 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (57% lower). The listed sponsor is Van Andel Research Institute, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Peripheral blood collection is the first listed.
NCT03526666 reports 2 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03526666 about?
NCT03526666 is a clinical study titled "Ascorbic Acid Levels in MDS, AML, and CMML Patients". This study is a non-interventional, specimen collection translational study to evaluate vitamin C levels in the peripheral blood of Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia (CMML) patients.
What is the current status of trial NCT03526666?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2017-11-01. Estimated completion is 2018-10-31.
What conditions does trial NCT03526666 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS.
What interventions are being tested in trial NCT03526666?
The interventions under investigation include: Peripheral blood collection (OTHER).
Who is sponsoring clinical trial NCT03526666?
This trial is sponsored by Van Andel Research Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03526666 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
RECRUITING
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.